Grant: Master's Award: Canada Graduate Scholarships
Université de Montréal
$27,000.00
Enhancing NK Cell Cytotoxicity Against Senescent Cancer Cells Through Pharmacological Screen
FY 2024-25
Summary
Cellular senescence, defined by permanent growth arrest, constitutes a natural defense mechanism against tumorigenesis, preventing the proliferation of damaged cells. Cancer cells can also adopt a senescence phenotype following cancer therapy. However, the accumulation of senescent cells, particularly after cancer therapy, can promote tumor growth relapse and metastasis through the senescence-associated secretory phenotype (SASP), which contains inflammatory molecules capable of interacting with neighboring cells. Ongoing research is focused on the development of treatments to selectively eliminate senescent cells, termed senolytics. Nevertheless, no senolytic drugs are currently approved for human use and cell-based senolytic approaches are therefore conceivable.Studies have shown that natural killer (NK) cells, a specific type of innate immune cell, can recognize and eliminate senescent cells. NK cells effectively display cytotoxic activity upon the recognition of target cells. However, some senescent cells remain resistant to elimination by NK cells via intrinsic resistance mechanisms. Thus, the goal of the current project is to improve the senolytic potential of NK cells in the context of cancer therapy by identifying compounds capable of enhancing their cytotoxicity against senescent cancer cells. We will perform a high-throughput pharmacological screen to identify these compounds using ovarian and prostate cancer cell lines both at pre-senescent and induced-senescent stages. Promising candidates will be further validated in dose-response experiments and mouse models. This work has a significant translational potential and could lead to improved cancer therapies and patient outcomes by optimizing NK cell-based senolytic approaches.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
529840
Name
Pusztai Erica
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Enhancing NK Cell Cytotoxicity Against Senescent Cancer Cells Through Pharmacological Screen
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Cell Therapy; Cellular Senescence; Cytotoxicity; Immunology; Ionizing Radiation; Nk Cells; Pharmacology; Tumor Cell Lines; Tumor Microenvironnement
Abstract
Cellular senescence, defined by permanent growth arrest, constitutes a natural defense mechanism against tumorigenesis, preventing the proliferation of damaged cells. Cancer cells can also adopt a senescence phenotype following cancer therapy. However, the accumulation of senescent cells, particularly after cancer therapy, can promote tumor growth relapse and metastasis through the senescence-associated secretory phenotype (SASP), which contains inflammatory molecules capable of interacting with neighboring cells. Ongoing research is focused on the development of treatments to selectively eliminate senescent cells, termed senolytics. Nevertheless, no senolytic drugs are currently approved for human use and cell-based senolytic approaches are therefore conceivable.Studies have shown that natural killer (NK) cells, a specific type of innate immune cell, can recognize and eliminate senescent cells. NK cells effectively display cytotoxic activity upon the recognition of target cells. However, some senescent cells remain resistant to elimination by NK cells via intrinsic resistance mechanisms. Thus, the goal of the current project is to improve the senolytic potential of NK cells in the context of cancer therapy by identifying compounds capable of enhancing their cytotoxicity against senescent cancer cells. We will perform a high-throughput pharmacological screen to identify these compounds using ovarian and prostate cancer cell lines both at pre-senescent and induced-senescent stages. Promising candidates will be further validated in dose-response experiments and mouse models. This work has a significant translational potential and could lead to improved cancer therapies and patient outcomes by optimizing NK cell-based senolytic approaches.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pusztai, Erica
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~